Mechanisms That Impact Cancer Risk With Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Key Information
Due Date: January 7, 2027
Agency: United States Department of Health and Human Services
Source: Federal
Funding Categories:
Funding Amount: Not Specified
Funding Type: Grant
Match Required: No
Status: Posted
Contact Info:
grantsinfo@nih.gov
NIH Grants Information grantsinfo@nih.gov
NIH Grants Information grantsinfo@nih.gov
Overview
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Show More
Key Dates
Posted Date: November 18, 2024
Application Due Date: January 7, 2027
Estimated Award Date: Not Specified
Additional Details
Eligible Applicants
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Small businesses
- Independent school districts
- Others
- Public and State controlled institutions of higher education
- State governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Public housing authorities/Indian housing authorities
- City or township governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- For profit organizations other than small businesses
- Special district governments
- Native American tribal governments (Federally recognized)